In contrast, the percentages of the CD3−CD16brCD56dim NK cells expressing inhibiting receptors NKG2A, KIR2DL1, and KIR3DL1 were not different between newly diagnosed CML patients and healthy controls (Figure 1A). The gene discussed is KLRC1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.